BIOVIE INC. Logo

BIOVIE INC.

Develops drug therapies for Alzheimer's, Parkinson's, and advanced liver diseases by targeting inflammation.

BIVI | US

Overview

Corporate Details

ISIN(s):
US09074F4054
LEI:
Country:
United States of America
Address:
680 W NYE LANE, 89703 CARSON CITY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BioVie Inc. is a clinical-stage biopharmaceutical company developing innovative drug therapies for chronic debilitating conditions, with a primary focus on neurological, neurodegenerative, and advanced liver diseases. The company's scientific approach posits that inflammation is a central factor in the progression of these disorders. Its lead therapeutic candidate, bezisterim, is a novel molecule being studied for the treatment of Alzheimer's and Parkinson's disease, aiming to modulate inflammation and enhance brain energy transfer. BioVie is also developing treatments for ascites, a common and life-threatening complication of advanced liver cirrhosis. The company's research incorporates advanced science, including the study of epigenetic mechanisms like DNA methylation to regulate gene expression.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BIOVIE INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BIOVIE INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BIOVIE INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel
PLUR
PLUS THERAPEUTICS, INC. Logo
Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.
United States of America
PSTV
PMV Pharmaceuticals, Inc. Logo
Developing small molecule therapies targeting p53 mutations to treat cancer.
United States of America
PMVP
A global supplier of generic APIs using AI to accelerate drug development.
South Korea
041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland
PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland
PPGN
PolyPid Ltd. Logo
Develops localized, prolonged-release drug therapies for surgery, oncology & metabolic diseases.
United States of America
PYPD
Praxis Precision Medicines, Inc. Logo
Developing therapies for CNS disorders using insights from genetic epilepsies.
United States of America
PRAX
PRECIGEN, INC. Logo
Develops gene and cell therapies for difficult-to-treat diseases using precision technology.
United States of America
PGEN
Precipio, Inc. Logo
Provides blood cancer diagnostic services & products to improve accuracy for physicians & labs.
United States of America
PRPO

Talk to a Data Expert

Have a question? We'll get back to you promptly.